Inogen (INGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
Annual Meeting scheduled for June 5, 2026, will be held virtually; shareholders can vote and submit questions online.
Recent operational and strategic turnaround led to a return to positive Adjusted EBITDA in 2025, with ongoing efforts to improve commercial execution and operational discipline.
Leadership strengthened with a new independent director and key senior management hires aligned with strategic priorities.
Active engagement with shareholders, including a new share repurchase program and a proposal to declassify the Board, reflecting a focus on accountability and value creation.
Voting matters and shareholder proposals
Election of two Class III directors for three-year terms.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Approval of the Amended and Restated 2023 Equity Incentive Plan, increasing share reserve by 750,000 shares.
Approval of an amendment to declassify the Board, transitioning to annual director elections by 2029.
Board of directors and corporate governance
Board consists of seven members, six of whom are independent; a new director, Vafa Jamali, appointed effective June 2026.
Board leadership structure requires separation of Chairperson and CEO roles; Chairperson must be independent.
Board diversity includes four women and three directors from underrepresented groups.
Four standing committees: Audit, Compensation, Compliance, and Nominating and Governance, all meeting independence requirements.
Active stockholder engagement led to governance changes, including the proposal to declassify the Board.
Latest events from Inogen
- Proxy details director elections, governance reforms, and expanded equity incentives for 2026.INGN
Proxy filing28 Apr 2026 - New products and leadership drive growth, margin expansion, and strategic transformation.INGN
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Diversifying into respiratory care, achieving financial turnaround, and launching innovative products.INGN
Company presentation20 Mar 2026 - Diversified portfolio and innovation pipeline set to drive growth and profitability.INGN
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - 2025 revenue rose 3.9–4% with improved profitability and a $30M buyback; 2026 targets 6% growth.INGN
Q4 202524 Feb 2026 - Q2 revenue up 6.1% to $88.8M, gross margin 48.1%, net loss narrowed, B2B led growth.INGN
Q2 20242 Feb 2026 - Q3 revenue up 5.8%, net loss narrows, gross margin rises, and adjusted EBITDA turns positive.INGN
Q3 202415 Jan 2026 - Leadership overhaul and channel optimization set the stage for profitable growth and innovation.INGN
Stifel 2024 Healthcare Conference13 Jan 2026 - Portfolio expansion and operational improvements position for growth in the under-penetrated respiratory market.INGN
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026